Everest Medicines Deal History & Licensing Activity
Everest Medicines is a biotech. Over the past three years, Everest Medicines has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 4 active clinical trials, primarily in Ophthalmology.
Deals (12mo)
3
Active Trials
4
Top Modality
Small Molecules
Focus Area
Ophthalmology
Everest Medicines Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Everest Medicines in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CARDAMYST (etripamil) | Milestone Pharmaceuticals | Small Molecules | Approved | license | Sep 3, 2026 |
| LNZ100 (aceclidine/brimonidine; US brand VIZZ / China brand CORXEL) | LENZ Therapeutics | Small Molecules | Approved | license | Jun 7, 2026 |
| civorebrutinib | Travere Therapeutics, Inc. | Small Molecules | Unknown | license | Jun 2, 2026 |
Everest Medicines Pipeline Focus
Therapeutic areas and modalities where Everest Medicines is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Everest Medicines Strategic Signals
Key indicators of Everest Medicines's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Everest Medicines Clinical Pipeline
Everest Medicines has 4 active clinical trials across 3 development phases.
1
Phase 1
1
Phase 1/2
2
Phase 2
See How Your Asset Matches Everest Medicines's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Everest Medicines Licensing & Deal Activity
Everest Medicines is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Everest Medicines ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Everest Medicines include Ophthalmology (3 deals and trials), Cardiovascular (2 deals and trials), Immunology (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Everest Medicines has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Everest Medicines and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Everest Medicines's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.